Inför Q1 från Remedy på måndag. Inderes Remedy Q1 on Monday: Our forecast sees AW2 royalties only starting to show in... Remedy will report its Q1 results on Monday at 9.00 am EEST. We will review the report afresh in Remedy earnings live starting at 8.55 am (in Finnish). We still expect a very weak quarter in terms of numbers before AW2 starts to generate royalties in...

A large YouTube channel is covering the trailer of Alan Wake. Warning: Spoilers from the game.

Here are a couple of examples of Alan Wake 2’s success. twitter.com Remedy Entertainment @remedygames Alan Wake 2 received honors at The Game Awards 2023, winning in Best Art Direction, Best Narrative, and Best Game Direction. Big thanks to everyone who voted in #thegameawards and congratulations to all the winners! 🏆 🎉 Read more: bit.ly/488Qgdm #alanwake #alanwake2 3:00 PM - 8 Dec 2023 4.2K 350

Här är analytikern @Atte_Riikola:s kommentarer om de senaste nyheterna från det här intressanta finska spelföretaget. Remedy announced on Thursday a strategic partnership agreement with Annapurna Pictures for Control 2. Remedy will self-publish the game, but Annapurna will fund 50% of the game and have the rights to extend the Control and Alan Wake brands into film and television. In our projections, we had assumed that Remedy would fund Control 2 entirely on its own and raise additional funds to do so. The current agreement is more balanced from a risk perspective and eliminates the need for additional funding that we had anticipated. At the same time, the deal offers good royalty potential and a low-risk opportunity to reach new audiences through movies and TV series. Overall, we view the deal as good for Remedy and will update our forecasts accordingly in the near future. Inderes Remedy finds good strategic partner for Control 2 - Inderes Remedy announced on Thursday a strategic partnership agreement with Annapurna Pictures for Control 2. Remedy will self-publish the game, but Annapurna will fund 50% of the game and have the rights to extend the Control and Alan Wake brands into...

BREAKING NEWS FROM REMEDY!!! Inderes Remedy acquires full rights to the Control franchise from 505 Games at a good... We see the agreement as very positive for Remedy's long-term potential, as the company is now in a strong position to decide to self-publish future Control games and/or to negotiate with a new publishing partner to finance projects on better terms.

Här är en färsk analys av Remedy. Inderes Remedy: AW2 sales figures fell short of our overly optimistic expectations -... Friday's sales figures for Alan Wake 2 show that the game is off to a good start and is Remedy's fastest selling game to date. However, following very positive critical reviews, we expected an even faster start and have now revised our overly... Friday’s sales figures for Alan Wake 2 show that the game is off to a good start and is Remedy’s fastest selling game to date. However, following very positive critical reviews, we expected an even faster start and have now revised our overly optimistic forecasts downwards.

Remedyn aktiekurs har sjunkit mycket, delvis av en anledning, men kanske till och med för mycket. Hur som helst, detta företag har skapat fantastiska spel, som Alan Wake. Jag gillar Inderes analyser eftersom de är ärliga. De är till exempel inte alltför tjuriga. Inderes Remedy: Back in the game - Inderes The investor sentiment around Remedy has recently soured, where we believe the key factors are the write-down of Vanguard’s development expenditure and the postponement of the financial statements based on publishing contract negotiations. In... The investor sentiment around Remedy has recently soured, where we believe the key factors are the write-down of Vanguard’s development expenditure and the postponement of the financial statements based on publishing contract negotiations. In addition, uncertainty about Alan Wake 2’s commercial success causes uncertainty around the stock. We believe that the content of the publishing contract and the sales figures of AW2 will be clarified in connection with the financial statements (3/20) at the latest, and with the decreased valuation we feel Remedy’s long-term potential looks interesting again.